NEWS
Morphocell Expands to California
with New Device Engineering Laboratory in Irvine
Irvine, Californie, le 14 mai 2026 – Nous sommes fiers d’annoncer l’ouverture du premier laboratoire de Morphocell à l’extérieur du Canada — une nouvelle installation de Morphocell USA Inc. consacrée au développement, à Irvine, en Californie.
While our U.S. headquarters and business presence have been established in Cambridge, Massachusetts, this marks our first dedicated lab on U.S. soil, a meaningful milestone in our growth and global expansion.
Located within the Orange County life sciences ecosystem at University Lab Partners, and led by Dr. Janahan Arulmoli, the Irvine lab will focus on Device Engineering, supporting our translational engineering and combination product development as we continue advancing next-generation regenerative medicine solutions for severe liver disease.
As we prepare for the clinical translation of ReLiver® and expand our platform capabilities, anchoring an engineering hub in Southern California strengthens our access to world-class MedTech expertise, engineering talent, and strategic collaborations within one of North America's leading innovation ecosystems.
Thank you to the University Lab Partners team for welcoming us into their community and supporting companies working to transform patient care through innovation.
This expansion reflects Morphocell's continued mission: harnessing advanced tissue engineering to deliver life-saving solutions for patients suffering from severe liver disease and other organ deficiencies.
From Montréal to Cambridge to Rome, and now Irvine. Morphocell continues to grow with global ambitions.
About Morphocell Technologies:
Morphocell Technologies, with his US subsidiary Morphocell USA Inc., is a regenerative medicine company developing stem cell–derived tissue and organ replacement therapies. Its proprietary allogeneic platform is designed to address severe organ deficiencies, beginning with liver disease. The company’s lead product, ReLiver®, is an off-the-shelf engineered liver tissue intended to temporarily replace liver function and enable regeneration without the need for immunosuppression. Morphocell is committed to transforming the treatment paradigm for liver failure and other life-threatening conditions through innovation in regenerative medicine.
Media Contact:
Zaynah Ibrahim
Operations Manager
+1 (514) 373-6444 ext. 106